🔎 Trials Near Me

Hjem › Tripelnegativ brystkreft › Nebraska

Kliniske studier for Tripelnegativ brystkreft i Nebraska

6 studier for Tripelnegativ brystkreft søker deltakere på steder i Nebraska.

Byer i Nebraska

Offisiell studietekst (engelsk)

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

  • Nebraska Cancer Specialists, Omaha
  • XCancer, Omaha
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07189871

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

  • University of Nebraska Medical Center, Omaha
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT06799065

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  • Cancer Partners of Nebraska ( Site 0068), Lincoln
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06966700

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  • Oncology Hematology West - Methodist, Omaha
  • Nebraska Methodist Hospital (change from Chi Health Bergan Mercy), Omaha
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT05633654

CtDNA Based MRD Testing for NAC Monitoring in TNBC

  • Nebraska Methodist, Omaha
RekruttererObservasjonsstudie
Alder 18 og eldre · Kvinner · Oppdatert 7. jan. 2025 · NCT06230185

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.